CGT · 다발성 골수종

141개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved141 programs
CGTLimited DatastaleBioray LaboratoriesPhase 2

BCMA-CART (BCMA-CART)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Discontinued
CGTLimited DatastaleMillennium Pharmaceuticals, Inc.Phase 2

ENK Cell Infusion (ENK Cell Infusion)

Asymptomatic Multiple Myeloma · Asymptomatic Multiple Myeloma

#AsymptomaticMultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 2Status Active
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Active
CGTLimited DatastaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleAutolus LimitedPhase 2

AUTO CAR T cell therapy (AUTO CAR T cell therapy)

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma · Patients Followed for up to 15 Years Fol

#PatientsFollowedforupto15YearsFo#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

Relapsed/Refractory Myeloma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

BCMA Targeted CAR T-cells (BCMA Targeted CAR T-cells)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleThe Pregene (ShenZhen) Biotechn…Phase 1

BCMA nanobody CAR-T cells (BCMA nanobody CAR-T cells)

Relapsed/Refractory Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastalePeking University People's Hosp…Phase 2

BCMA-CD19 CAR-T therapy (BCMA-CD19 CAR-T therapy)

Systemic Lupus Erythematosus; Inflammatory Myopathy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CS1 cCAR T cells (BCMA-CS1 cCAR T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

BCMA-PD1-CART Cell (BCMA-PD1-CART Cell)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active

3 / 8 pages

← PreviousNext →